Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated With Immune Activation In Patients With Recurrent High-Grade Glioma Treated With CAN-3110
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics (NASDAQ:CADL) announced that Nature published results from the ongoing first-in-human phase 1 clinical trial of CAN-3110, a herpes simplex virus-1 oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma. The study showed that CAN-3110 was well tolerated and treatment was associated with improved survival. The company is currently evaluating the effects of multiple CAN-3110 injections in recurrent high-grade glioma.
October 18, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics' CAN-3110 has shown promising results in a phase 1 clinical trial, potentially improving survival in patients with recurrent high-grade glioma. This could positively impact the company's stock in the short term.
The positive results from the phase 1 clinical trial of CAN-3110 could increase investor confidence in Candel Therapeutics, potentially leading to an increase in the company's stock price. The company's focus on developing novel therapies for recurrent high-grade glioma, a condition with limited treatment options, could also contribute to this positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100